APA (7th ed.) Citation

Margolis, D. A., Gonzalez-Garcia, J., Stellbrink, H., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., . . . Sutton, K. C. (2017). Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet, 390(10101), 1499. https://doi.org/10.1016/S0140-6736(17)31917-7

Chicago Style (17th ed.) Citation

Margolis, David A., et al. "Long-acting Intramuscular Cabotegravir and Rilpivirine in Adults with HIV-1 Infection (LATTE-2): 96-week Results of a Randomised, Open-label, Phase 2b, Non-inferiority Trial." Lancet 390, no. 10101 (2017): 1499. https://doi.org/10.1016/S0140-6736(17)31917-7.

MLA (9th ed.) Citation

Margolis, David A., et al. "Long-acting Intramuscular Cabotegravir and Rilpivirine in Adults with HIV-1 Infection (LATTE-2): 96-week Results of a Randomised, Open-label, Phase 2b, Non-inferiority Trial." Lancet, vol. 390, no. 10101, 2017, p. 1499, https://doi.org/10.1016/S0140-6736(17)31917-7.